Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

PURPOSE: Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Ramanathan, Ramesh K., McDonough, Shannon L., Philip, Philip A., Hingorani, Sunil R., Lacy, Jill, Kortmansky, Jeremy S., Thumar, Jaykumar, Chiorean, E. Gabriela, Shields, Anthony F., Behl, Deepti, Mehan, Paul T., Gaur, Rakesh, Seery, Tara, Guthrie, Katherine A., Hochster, Howard S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494359/
https://ncbi.nlm.nih.gov/pubmed/30817250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01295
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars